Skip to Content
Merck

Key Documents

View All Documentation

F9005

Flufenamic acid

analytical standard, for drug analysis

Synonym(s):

N-(3-[Trifluoromethyl]phenyl)anthranilic acid, N-(α,α,α-Trifluoro-m-tolyl)anthranilic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Linear Formula:
2-(CF3C6H4NH)C6H4CO2H
CAS Number:
530-78-9
Molecular Weight:
281.23
NACRES:
NA.24
PubChem Substance ID:
329799777
UNSPSC Code:
41116107
EC Number:
208-494-1
MDL number:
MFCD00002422
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

132-135 °C (lit.)

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

SMILES string

OC(=O)c1ccccc1Nc2cccc(c2)C(F)(F)F

InChI

1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)

InChI key

LPEPZBJOKDYZAD-UHFFFAOYSA-N

General description

Flufenamic acid, a non-steroidal anti-inflammatory drug, is an effective analgesic agent.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Flufenamic acid has been used as a standard in studying the two well defined, polymorphs of flufenamic acid like form I and form III, using solid-state density functional theory and terahertz spectroscopy.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCN1442
BCCL7651
BCCK1277
BCCK8356
BCCJ5571

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Minsoo Kim et al.
Pharmaceutics, 11(3) (2019-03-22)
Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs. This study was designed to evaluate
Conformational origins of polymorphism in two forms of flufenamic acid
Delaney P S, et al.
Journal of Molecular Structure, 1078, 83-89 (2014)
Julia C Schwarz et al.
International journal of pharmaceutics, 437(1-2), 83-88 (2012-08-21)
Nanocarriers are highly interesting delivery systems for the dermal application of drugs. Based on a eudermic alkylpolyglycosid nanoemulsions, solid lipid nanoparticles (SLN) and nano-structured lipid carriers (NLC) were prepared by ultrasonic dispersion. The ultrasound preparation technique turned out to be
View All Related Papers